Effect of early application of a sodium-glucose cotransporter-2 inhibitor on ventricular remodelling and prognosis in patients with anterior wall acute myocardial infarction.
Fangyuan Chen, Ping Liu, Ling Bai, Juanli Li, Tao Chen
{"title":"Effect of early application of a sodium-glucose cotransporter-2 inhibitor on ventricular remodelling and prognosis in patients with anterior wall acute myocardial infarction.","authors":"Fangyuan Chen, Ping Liu, Ling Bai, Juanli Li, Tao Chen","doi":"10.1016/j.acvd.2024.11.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of sodium-glucose cotransporter-2 inhibitors in patients with acute myocardial infarction remains elusive.</p><p><strong>Aim: </strong>To evaluate the effect of early application of a sodium-glucose cotransporter-2 inhibitor on ventricular remodelling and prognosis in patients with anterior wall acute myocardial infarction.</p><p><strong>Methods: </strong>In this prospective study, 102 patients diagnosed with anterior wall acute myocardial infarction were enrolled and divided into intervention and control groups according to the use of dapagliflozin within 24hours after admission. Demographic and clinical data, including age, sex, associated co-morbidities, number of lesions, length of hospital stay, N-terminal prohormone of brain natriuretic peptide, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic diameters and drug-related adverse reactions, were collected and analysed between the two groups. All patients were followed up 1, 3 and 6 months after discharge.</p><p><strong>Results: </strong>At 6 months, left ventricular ejection fraction was higher (55.98±7.17% vs. 52.71±7.78%; P=0.03) and N-terminal prohormone of brain natriuretic peptide was lower (141.52±83.18 vs. 203.69±152.13pg/mL; P=0.01) in the intervention group versus the control group. Left ventricular end-systolic diameter (35.68±4.32 vs. 38.00±5.01mm; P=0.01) and left ventricular end-diastolic diameter (50.48±4.90 vs. 52.67±4.91mm; P=0.03) were smaller in the intervention group versus the control group. Event-free survival rates were better in the intervention group than in the control group (90% vs. 74.5%; P=0.03). The cumulative incidence of drug-related adverse reactions was similar in the two groups (14% vs. 4.0%; P=0.15).</p><p><strong>Conclusions: </strong>Use of dapagliflozin within 24hours after admission can improve cardiac function, inhibit ventricular remodelling, improve clinical prognosis and have high safety in patients with anterior wall acute myocardial infarction during 6-month follow-up.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.acvd.2024.11.003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The role of sodium-glucose cotransporter-2 inhibitors in patients with acute myocardial infarction remains elusive.
Aim: To evaluate the effect of early application of a sodium-glucose cotransporter-2 inhibitor on ventricular remodelling and prognosis in patients with anterior wall acute myocardial infarction.
Methods: In this prospective study, 102 patients diagnosed with anterior wall acute myocardial infarction were enrolled and divided into intervention and control groups according to the use of dapagliflozin within 24hours after admission. Demographic and clinical data, including age, sex, associated co-morbidities, number of lesions, length of hospital stay, N-terminal prohormone of brain natriuretic peptide, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic diameters and drug-related adverse reactions, were collected and analysed between the two groups. All patients were followed up 1, 3 and 6 months after discharge.
Results: At 6 months, left ventricular ejection fraction was higher (55.98±7.17% vs. 52.71±7.78%; P=0.03) and N-terminal prohormone of brain natriuretic peptide was lower (141.52±83.18 vs. 203.69±152.13pg/mL; P=0.01) in the intervention group versus the control group. Left ventricular end-systolic diameter (35.68±4.32 vs. 38.00±5.01mm; P=0.01) and left ventricular end-diastolic diameter (50.48±4.90 vs. 52.67±4.91mm; P=0.03) were smaller in the intervention group versus the control group. Event-free survival rates were better in the intervention group than in the control group (90% vs. 74.5%; P=0.03). The cumulative incidence of drug-related adverse reactions was similar in the two groups (14% vs. 4.0%; P=0.15).
Conclusions: Use of dapagliflozin within 24hours after admission can improve cardiac function, inhibit ventricular remodelling, improve clinical prognosis and have high safety in patients with anterior wall acute myocardial infarction during 6-month follow-up.
期刊介绍：
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
